A study conducted by researchers at the University of Rochester and Harvard University revealed that Pfizer's COVID-19 pill, Paxlovid, was underutilized in nursing homes, despite its proven efficacy. The study found that only about 25% of nursing home residents with COVID-19 were prescribed any antiviral medication from May 2021 to December 2022. The underuse of Paxlovid likely led to a significant amount of avoidable mortality, according to Harvard professor Michael Barnett.